Omega Therapeutics, Inc.: Nasdaq/NYSE listing notice — Omega Therapeutics files Ch. 11, stalking horse asset sale to Flagship affiliate for $11.5M, Nasdaq delisting

Omega Therapeutics, Inc.

Filed Chapter 11 on Feb 10, 2025; entered Stalking Horse APA with PM08-B (Flagship affiliate) for $11.46M credit bid.
Nasdaq notified delisting due to Chapter 11 filing; trading suspended Feb 25, 2025; Company not appealing.
Proposed sale process: bid deadline April 1, 2025; auction April 3; sale hearing April 10.
Company operates as debtor-in-possession under Bankruptcy Court jurisdiction.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Omega Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1, 5450(a)(1)).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101, 5110(b), IM-5101-1, 5450(a)(1)

Exact text from the filing

February 18, 2025, Company received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq had determined to delist the Company’s common stock, par value $0.001 per share (the “Common Stock”). Nasdaq reached its decision that the Company is no longer suitable for listing pursuant to Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the Company’s commencement of the Chapter 11 Case on February 10, 2025. The Notice also indicated that concerns about the Company’s ability to sustain compli

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-25-033500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.